General Assembly 2012 - 2015
The General Assembly is the legislative body of the EORTC. Policies, proposals, and strategies are discussed and approved by the General Assembly. The General Assembly delegates specific functions to the Board, Committees, or appointed persons.
The EORTC Network is organized into groups of scientists and/or clinicians, each with a specific area of interest in cancer research. These groups conduct translational research and/or clinical trials on all types of cancers using a multidisciplinary approach. The effective voting members of the General assembly are the President, the past three Presidents, each Group Chair, the Task Force Chairs, each of the Committee Chairs, and a representative from each of the top 15 accruing institutions. The General Assembly meets at least once a year and elects a new EORTC Board once every three years.
EFFECTIVE VOTING MEMBERS
| Acting President | R. Stupp, Lausanne/Zurich (CH) |
| Past Presidents (last three): | JY. Blay, Lyon (FR) |
| M. Piccart, Brussels (BE) | |
| A.M.M. Eggermont, Villejuif (FR) |
EORTC Groups Chairs
| Brain Tumor | W. Wick, Heidelberg (DE) |
| Breast Cancer | D. Cameron, Edinburgh (UK) |
| Children's Leukemia | Y. Benoit, Gent (BE) |
| Gastrointestinal Tract Cancer | A. Roth, Geneva (CH) |
| Genito-Urinary Cancers | B. Tombal, Brussels BE) |
| Gynecological Cancer | A. Casado-Herraez, Madrid (ES) |
| Head and Neck Cancer | L. Licitra, Milano (IT) |
| Imaging | N. deSouza, Sutton (UK) |
| Infectious Diseases | P. Donnelly, Nijmegen (NL) |
| Leukemia | F. Baron, Liège (BE) |
| Lung Cancer | M. O'Brien, Sutton (UK) |
| Lymphoma | R. van der Maazen, Nijmegen (NL) |
| Melanoma | A. Testori, Milano (IT) |
| PathoBiology | J. Martens, Rotterdam (NL) |
| Pharmacology and Molecular Mechanisms Group | G.J. Peters, Amsterdam (NL) |
| Quality of Life | M. Groenvold, Copenhagen (DK) |
| Radiation Oncology | Ph. Maingon, Dijon (FR) |
| Soft Tissue and Bone Sarcoma | W. van der Graaf, Nijmegen (NL) |
EORTC Task Forces Chairs
| Cancer in the Elderly | H. Wildiers, Leuven (BE) |
| Cutaneous Lymphoma | R. Stadler, Minden (DE) |
| Endocrine Tumors | M. Schlumberger, Villejuif (FR) |
EORTC Committees / Divisions Chairs
- Clinical Research Division: M. van den Bent, Rotterdam (NL)
- Translational Research Division: N. Harbeck, Munich (DE)
- Independent Data Monitoring Committee: A. Awada, Brussels (BE)
- Membership Committee: P. Rutkowski, Warsaw (PL)
- New Drug Advisory Committee: C. Dittrich, Vienna (AT)
- Protocol Review Committee: F. Shepherd, Toronto (CA)
- Translational Research Advisory Committee: S. Tejpar, Leuven (BE)
- Quality Assurance Committee: K. Haustermans, Leuven (BE)
- Scientific Audit Committee: I. Tannock, Toronto (CA)
Representatives from the 15 top Academic Recruiting Institutions
|
Institut Curie, Paris & Saint-Cloud (FR) |
V. Diéras |
|
Institut Gustave Roussy, Villejuif (FR) |
M. Ducreux |
|
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam (NL) |
E. Rutgers |
|
Clinique Sainte Elisabeth, Namur (BE) |
P. Vuylsteke |
|
Hôpitaux Universitaires Bordet-Erasme, Brussels (BE) |
A. Awada |
|
Centre Georges-François-Leclerc, Dijon (FR) |
P. Fumoleau |
|
UZ Leuven, Leuven (BE) |
I. Vergote |
|
Leiden University Medical Centre, Leiden (NL) |
H. Gelderblom |
|
Universitaetsklinikum Heidelberg, Heidelberg (DE) |
M. Platten |
|
Christie NHS Foundation Trust, Manchester (GB) |
C. Faivre-Finn |
|
Centre Léon Bérard, Lyon (FR) |
O. Tredan |
|
Universitaetsspital, Zurich (CH) |
M. Weller |
|
Arnhem’s Radiotherapeutisch Instituut, Arnhem & Harderwijk (NL) |
R. Keus |
|
UZ Rotterdam, Rotterdam (NL) |
S. Sleijfer |
|
Medisch Centrum Haaglanden, Den Haag & Leidschendam (NL) |
M. Taphoorn |
GENERAL ASSEMBLY EFFECTIVE NON-VOTING MEMBERS
Board Members
| Vice-President | V. Grégoire, Brussels (BE) |
| Secretary General | F. Cardoso, Lisbon (PT) |
| Treasurer | E. Rutgers, Amsterdam (NL) |
| Members | D. Fennell, Leicester (UK) |
| E. Van Cutsem, Leuven (BE) | |
| J. van Meerbeeck, Gent (BE) |
Other Effective Members
- Director General, EORTC: F. Meunier, Brussels (BE)
- Director, EORTC: D. Lacombe, Brussels (BE)
- Chair, EORTC Charitable Trust: Sir Christopher Mallaby, London (UK)
- Editor-in-Chief, European Journal of Cancer: A.M.M. Eggermont, Villejuif (FR)
- EJC Liaison Officer: J.C. Horiot, Genolier (CH)
- Executive Secretary, EORTC Charitable Trust: V. Agnew, London (UK)
- Director European Activities, NCI Center for Global Health European Liaison Office: S. Radtke, Brussels (BE)
Past Presidents (other than the last 3)
- A.T. van Oosterom, BE (2000-2003)
- JC. Horiot, FR (1997-2000)
- JG. McVie, UK (1994-1997)
- L. Denis, BE (1988-1991)
- U. Veronesi, IT (1985-1988)
- D. van Bekkum, NL (1969-1975)
- S. Garattini, IT (1965-1968)
